Elite 50% OFF Act now – get top investing tools Register Now!

Immix Biopharma, Inc.

Contributing Author

Recent Articles by Immix Biopharma, Inc.

Nov-12	Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch IMMX GlobeNewswire
Nov-03	Immix Biopharma's NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025 IMMX GlobeNewswire
Oct-14	Immix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference IMMX GlobeNewswire
Oct-06	Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting IMMX GlobeNewswire
Oct-01	Immix Biopharma to Present at the 37th Annual Piper Sandler Healthcare Conference IMMX GlobeNewswire
Sep-18	Immix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2 IMMX GlobeNewswire
Sep-11	Nancy T. Chang, Proven Biotechnology Leader, Joins Immix Biopharma Board of Directors IMMX GlobeNewswire
Sep-08	Immix Biopharma Announces Strategic Investment by Houston based Goose Capital, led by founding member Dr. Nancy T. Chang IMMX GlobeNewswire
Aug-25	Immix Biopharma to Present at the Stifel 2025 Healthcare Conference IMMX GlobeNewswire
Aug-06	Immix Biopharma Announces Other Serious Diseases Strategy IMMX GlobeNewswire
Jul-11	Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion IMMX GlobeNewswire
Jul-07	Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis IMMX GlobeNewswire
Jun-06	Immix Biopharma Attends FDA CEO Forum in Washington DC IMMX GlobeNewswire
Jun-03	Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis IMMX GlobeNewswire
May-23	Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2 IMMX GlobeNewswire
May-22	Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis IMMX GlobeNewswire
May-21	Immix Biopharma to Host KOL Event to Discuss NXC-201 Clinical Data Presented at ASCO 2025 in relapsed/refractory AL Amyloidosis IMMX GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.